Summit Global Investments Has $388,000 Holdings in Johnson & Johnson (NYSE:JNJ)

Summit Global Investments lessened its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 43.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,685 shares of the company's stock after selling 2,069 shares during the period. Summit Global Investments' holdings in Johnson & Johnson were worth $388,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in JNJ. Millstone Evans Group LLC bought a new position in Johnson & Johnson in the fourth quarter worth $1,449,000. Washington Trust Bank raised its stake in shares of Johnson & Johnson by 4.5% in the 4th quarter. Washington Trust Bank now owns 19,163 shares of the company's stock valued at $2,771,000 after buying an additional 828 shares in the last quarter. MRP Capital Investments LLC lifted its holdings in shares of Johnson & Johnson by 4.1% during the 4th quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock worth $237,000 after acquiring an additional 65 shares during the period. Sector Gamma AS bought a new stake in Johnson & Johnson in the fourth quarter valued at about $11,280,000. Finally, Wayfinding Financial LLC acquired a new position in Johnson & Johnson in the fourth quarter worth about $1,071,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have weighed in on JNJ. Raymond James decreased their price objective on Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating on the stock in a report on Thursday, January 23rd. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research note on Monday, March 10th. Barclays boosted their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an "equal weight" rating in a research note on Tuesday, January 28th. Wells Fargo & Company dropped their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a research report on Thursday, January 23rd. Finally, Citigroup decreased their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a research note on Wednesday, December 11th. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $171.33.

Remove Ads

Johnson & Johnson Trading Up 0.9 %

Shares of JNJ traded up $1.50 on Thursday, reaching $163.22. 6,750,116 shares of the company's stock were exchanged, compared to its average volume of 7,079,291. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The stock has a market capitalization of $393.33 billion, a P/E ratio of 24.54, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The business has a 50 day moving average price of $158.35 and a two-hundred day moving average price of $156.23.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the prior year, the business posted $2.29 EPS. The firm's quarterly revenue was up 5.3% on a year-over-year basis. Research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were given a dividend of $1.24 per share. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.04%. Johnson & Johnson's payout ratio is currently 74.59%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares of the company's stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.